Skip to content

Arcutis Biotherapeutics, Inc. ARQT Amortization of capitalized software and acquired intangible assets

Amortization of capitalized software and acquired intangible assets at other companies

AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%
Free cash flow$2.2M+107%

Valuation

See full
Market cap$3.29B+57.5%

Profitability

See full
Gross margin90.9%+2.5pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s amortization of capitalized software and acquired intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s amortization of capitalized software and acquired intangible assets?
Arcutis Biotherapeutics, Inc. (ARQT) reported amortization of capitalized software and acquired intangible assets of $562K in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s amortization of capitalized software and acquired intangible assets changed year-over-year?
Arcutis Biotherapeutics, Inc.'s amortization of capitalized software and acquired intangible assets decreased by 81.1% year-over-year, from $2.98M to $562K.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s amortization of capitalized software and acquired intangible assets?
Over 3 years (2022 to 2025), Arcutis Biotherapeutics, Inc.'s amortization of capitalized software and acquired intangible assets has grown at a 146.4% compound annual growth rate (CAGR), from $312K to $4.67M.